VedTechBio enhances RxAgentAI platform; teams with US-based AlphaMeld to cut drug discovery time and co-develop therapies for rare and metabolic diseases.
SHANGHAI, July 30, 2025 /PRNewswire/ -- CreateAI Holdings ("CreateAI" or the "Company") (OTC: TSPH), a leader in applied artificial intelligence technology, will debut major...
- 2026 Kia Sportage Hybrid has a starting MSRP of $30,2901- Standard and X-Line models blend comfort and functionality- Styling enhancements further elevate the...
LAKELAND, Fla., July 30, 2025 /PRNewswire/ -- Florida Southern College has once again been recognized among the nation's best by The Princeton Review, with...
ABUJA, Nigeria and NEWPORT BEACH, Calif., July 30, 2025 /CNW/ -- In a landmark collaboration aimed at accelerating innovation, capacity building, and digital transformation...
ABUJA, Nigeria and NEWPORT BEACH, Calif., July 30, 2025 /PRNewswire/ -- In a landmark collaboration aimed at accelerating innovation, capacity building, and digital transformation...
ABUJA, Nigeria and NEWPORT BEACH, Calif., July 30, 2025 /PRNewswire/ -- In a landmark collaboration aimed at accelerating innovation, capacity building, and digital transformation...
ABUJA, Nigeria and NEWPORT BEACH, Calif., July 31, 2025 /PRNewswire/ -- In a landmark collaboration aimed at accelerating innovation, capacity building, and digital transformation...
SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...
SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...
- 2026 Kia Sportage Hybrid has a starting MSRP of $30,2901- Standard and X-Line models blend comfort and functionality- Styling enhancements further elevate the...
The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...
The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...
The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...